Tag: 4DMT

Cell and Gene Therapy, Industry

4DMT gene therapy cuts need for Eylea in wet AMD trial

February 5, 2024

Via: Pharmaphorum

On the strength of the results, 4DMT is planning to start a phase 3 trial of the gene therapy by the end of the first quarter of 2025. The data from the phase 2 PRISM study comes from a cohort […]

Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

4D Molecular Therapeutics Raises $75 Million in Series C Financing

June 16, 2020

Via: BioSpace

4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced the closing of its $75 million Series C financing. The round was led by Viking Global Investors, with participation from […]